搜索
Aytu Biopharma Inc
AYTU添加自选
2.160USD
+0.010+0.47%
收盘 07/01, 16:00（美东）报价延迟15分钟
23.18M总市值
亏损市盈率 TTM
关键数据
2.130今开
2.190最高
7.28K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.07%换手率
2.150昨收
2.120最低
12.77K成交额
亏损市盈率静
1.63市净率
0.00%股息率 TTM
-28.93%ROA
3.06552周最高
0.32量比
-13.56M净利润
10.73M总股本
-4.6080每股收益TTM
0.25Beta
-97.42%ROE
1.46052周最低
3.26%振幅
55.10%毛利率
23.18M总市值
0.71回报/风险
3.37%风险率
TradingKey Aytu Biopharma Inc股票评分
单位: USD 更新时间: 2026-06-30操作建议
Aytu Biopharma Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在药品行业排名85/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.50。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aytu Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Aytu Biopharma Inc亮点
亮点风险
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
业绩增长期
公司处于发展阶段，最新年度总收入66.38M美元
估值高估
公司最新PE估值-0.47，处于3年历史高位
机构减仓
最新机构持股3.87M股，环比减少11.30%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
分析师目标
根据
3
位分析师
买入
评级
9.500
目标均价
+333.79%
涨幅空间
Aytu Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aytu Biopharma Inc简介
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
公司代码AYTU
公司Aytu Biopharma Inc
CEODisbrow (Joshua R)
网址https://aytubio.com/
相关品种
热门品种
常见问题
Aytu Biopharma Inc(AYTU)的当前股价是多少？
Aytu Biopharma Inc(AYTU)的当前股价是 2.15。
Aytu Biopharma Inc的股票代码是什么？
Aytu Biopharma Inc的股票代码是AYTU。
Aytu Biopharma Inc股票的52周最高点是多少？
Aytu Biopharma Inc股票的52周最高点是3.06。
Aytu Biopharma Inc股票的52周最低点是多少？
Aytu Biopharma Inc股票的52周最低点是1.46。
Aytu Biopharma Inc的市值是多少？
Aytu Biopharma Inc的市值是23.08M。
现在Aytu Biopharma Inc(AYTU)的股票是买入、持有还是卖出？
根据分析师评级，Aytu Biopharma Inc(AYTU)的总体评级为买入，目标价格为9.50。
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是多少
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是-2.16。